Construction of a Prognostic Immune-Related LncRNA Risk Model for Gastric Cancer

Table 2

Univariate analysis of overall survival and disease-free survival.

	Overall survival			Disease-free survival
	HR	95% CI	value	HR	95% CI	value
MIR4435-1HG	1.34	[1.03–1.76]	0.03	1.44	[1.04–1.97]	0.03
H19	1.06	[0.98–1.14]	0.15	1.04	[0.96–1.14]	0.34
RP11-617F23.1	0.87	[0.71–1.06]	0.16	0.77	[0.59–0.99]	0.04
FLJ22763	0.83	[0.61–1.14]	0.26	0.84	[0.58–1.22]	0.36
RP11-253E3.3	0.9	[0.63–1.28]	0.55	0.9	[0.57–1.41]	0.64
UCA1	1.02	[0.94–1.12]	0.58	1.11	[1.01–1.23]	0.03
LINC00152	1.07	[0.83–1.37]	0.61	1.14	[0.85–1.54]	0.38
RP1-302G2.5	1.01	[0.74–1.38]	0.94	1.08	[0.76–1.54]	0.67

Note: overall survival, β_MIR4435-1HG = 0.29; disease-free survival, β_MIR4435-1HG = 0.22, β_UCA1 = 0.08, and β_{RP11-617F23.1} = −0.16; statistically significant.